We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.00 | 0.06% | 1,819.00 | 1,819.00 | 1,821.00 | 1,832.00 | 1,813.00 | 1,825.00 | 396,909 | 16:35:16 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 20.96 | 4.02B |
Acorda Therapeutics Inc. (ACOR) were down 14.8%, to $24.45, Wednesday afternoon as a federal appeals court denied the company's motion for an injunction in its patent litigation with generic drug companies. In 2017, after a district court upheld one patent for multiple sclerosis treatment Ampyra, but invalidated four others, Acorda said it would cut about 20% of its workforce. If the appeals court doesn't overturn the district court's decision by July 30, "multiple generic drug manufacturers may decide to launch at-risk generic versions of Ampyra," the company said in a filing. (josh.beckerman@wsj.com)
(END) Dow Jones Newswires
July 25, 2018 14:21 ET (18:21 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Hikma Pharmaceuticals Chart |
1 Month Hikma Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions